LIVIVO - Das Suchportal für Lebenswissenschaften

switch to English language
Erweiterte Suche

Ihre letzten Suchen

  1. AU="Jessa R. Alexander"
  2. AU=Rauner Martina
  3. AU="Richlen, Mindy L"
  4. AU="Merghani, Nada M"
  5. AU=Splitt M P
  6. AU="Zlatanović, Gordana"

Suchergebnis

Treffer 1 - 1 von insgesamt 1

Suchoptionen

Artikel ; Online: Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine–induced antibody and T cell immunity and function

Joseph J. Sabatino Jr. / Kristen Mittl / William M. Rowles / Kira McPolin / Jayant V. Rajan / Matthew T. Laurie / Colin R. Zamecnik / Ravi Dandekar / Bonny D. Alvarenga / Rita P. Loudermilk / Chloe Gerungan / Collin M. Spencer / Sharon A. Sagan / Danillo G. Augusto / Jessa R. Alexander / Joseph L. DeRisi / Jill A. Hollenbach / Michael R. Wilson / Scott S. Zamvil /
Riley Bove

JCI Insight, Vol 7, Iss

2022  Band 4

Abstract: BACKGROUND Vaccine-elicited adaptive immunity is a prerequisite for control of SARS-CoV-2 infection. Multiple sclerosis (MS) disease-modifying therapies (DMTs) differentially target humoral and cellular immunity. A comprehensive comparison of the effects ...

Abstract BACKGROUND Vaccine-elicited adaptive immunity is a prerequisite for control of SARS-CoV-2 infection. Multiple sclerosis (MS) disease-modifying therapies (DMTs) differentially target humoral and cellular immunity. A comprehensive comparison of the effects of MS DMTs on SARS-CoV-2 vaccine–specific immunity is needed, including quantitative and functional B and T cell responses.METHODS Spike-specific Ab and T cell responses were measured before and following SARS-CoV-2 vaccination in a cohort of 80 study participants, including healthy controls and patients with MS in 6 DMT groups: untreated and treated with glatiramer acetate (GA), dimethyl fumarate (DMF), natalizumab (NTZ), sphingosine-1-phosphate (S1P) receptor modulators, and anti-CD20 mAbs. Anti–spike-Ab responses were assessed by Luminex assay, VirScan, and pseudovirus neutralization. Spike-specific CD4+ and CD8+ T cell responses were characterized by activation-induced marker and cytokine expression and tetramer.RESULTS Anti-spike IgG levels were similar between healthy control participants and patients with untreated MS and those receiving GA, DMF, or NTZ but were reduced in anti-CD20 mAb– and S1P-treated patients. Anti-spike seropositivity in anti-CD20 mAb–treated patients was correlated with CD19+ B cell levels and inversely correlated with cumulative treatment duration. Spike epitope reactivity and pseudovirus neutralization were reduced in anti-CD20 mAb– and S1P-treated patients. Spike-specific CD4+ and CD8+ T cell reactivity remained robust across all groups, except in S1P-treated patients, in whom postvaccine CD4+ T cell responses were attenuated.CONCLUSION These findings from a large cohort of patients with MS exposed to a wide spectrum of MS immunotherapies have important implications for treatment-specific COVID-19 clinical guidelines.FUNDING NIH grants 1K08NS107619, K08NS096117, R01AI159260, R01NS092835, R01AI131624, and R21NS108159; NMSS grants TA-1903-33713 and RG1701-26628; Westridge Foundation; Chan Zuckerberg Biohub; Maisin Foundation.
Schlagwörter Autoimmunity ; COVID-19 ; Medicine ; R
Thema/Rubrik (Code) 616
Sprache Englisch
Erscheinungsdatum 2022-03-01T00:00:00Z
Verlag American Society for Clinical investigation
Dokumenttyp Artikel ; Online
Datenquelle BASE - Bielefeld Academic Search Engine (Lebenswissenschaftliche Auswahl)

Zusatzmaterialien

Kategorien

Zum Seitenanfang